Skip to main content
Home

Breadcrumb

  1. Home
  2. News
  3. Search results
Displaying results 101 - 125 of 624 Clear search
Zyme Communications
Pierre Arsène, Founder and CEO, Mursla Bio
Healthcare and Life Science 13 Nov 2025

Mursla Bio collaborates with a leading global pharma company to advance biomarker-guided precision medicine in MASH

Mursla Bio’s AI Precision Medicine Platform to inform drug development and patient stratification in metabolic liver disease

Zyme Communications
Henry Miller, Ph.D., Head of Machine Learning, Shift Bioscience
Healthcare and Life Science, Information Technology and Telecoms 11 Nov 2025

Shift Bioscience publishes improved metric calibration framework for robust genetic perturbation modeling using AI Virtual Cells

AI virtual cells outperform key baselines on well-calibrated metrics, challenging prior reports of poor model performance Foundational research reinforces the use of virtual
Zyme Communications
Dr Nicola Thompson, CEO, TRIMTECH Therapeutics and Dr Mike Hutton, SAB Member, TRIMTECH Therapeutics
Healthcare and Life Science 11 Nov 2025

TRIMTECH Therapeutics appoints Dr Mike Hutton to Scientific Advisory Board

·       Industry leader brings deep expertise across neurodegenerative disease therapeutics development ·       Dr Hutton joins Prof. Alessio Ciulli FRS and Dr Adam Gilbert on SAB

Zyme Communications
SPT Labtech’s firefly® liquid handling platform
Healthcare and Life Science 05 Nov 2025

SPT Labtech and Alithea Genomics collaborate to automate ultra sensitive single-cell transcriptomic workflows

Integrates Alithea Genomics’ MERCURIUS FLASH-seq single-cell RNA-seq protocol with SPT Labtech’s firefly liquid handling platform Enables higher-throughput, cost efficient single-cell sequencing

Cambridge, UK, and Lausanne, Switzerland, 05 Novem

Zyme Communications
Edmund Champness, Chief Scientific Officer at Optibrium
Healthcare and Life Science 04 Nov 2025

Optibrium delivers real-time collaboration in its comprehensive molecular design platform with StarDrop 8

Latest release accelerates hit-to-candidate progression by keeping teams aligned, eliminating inefficiencies and enabling better prioritisation decisions

Zyme Communications
Klaus Orlinger, PhD., CSO, VALANX Biotech
Healthcare and Life Science 30 Oct 2025

VALANX Biotech appoints Klaus Orlinger, PhD. as Chief Scientific Officer

Strategic hire of industry expert bolsters leadership team as Company progresses first antibody drug conjugate to candidate selection phaseAppointment will drive development of VALANX’ GoldenSite™ platform to advance development of best-in-class therapeutic protein conj
Zyme Communications
ProImmune
Healthcare and Life Science 30 Oct 2025

ProImmune Ltd introduces ProVE® SL Self-Loading MHC Class I Monomers to improve T cell research flexibility

Oxford, UK – 30 October 2025 – ProImmune Ltd, a global leader in life science reagents and services, announces the launch of its new ProVE® SL Self-Loading MHC Class I Monomers.

Zyme Communications
www.qureight.com
Healthcare and Life Science, Science and Engineering 27 Oct 2025

Qureight’s Vascul8 model validated to improve care for pulmonary vascular disorders

Study published in ‘American Journal of Respiratory Cell and Molecular Biology’ validates Qureight’s deep-learning models and imaging platform beyond fibrotic lung disease, into new therapeutic areas for severe respiratory diseaseData demonstrate sensitive quantificatio
Zyme Communications
logo
Healthcare and Life Science 23 Oct 2025

OMED Health Partners with Aviva to support the digestive health of employees

75 Aviva employees to gain pilot access to doctor-led OMED Health Plans, which include the use of the OMED Health Breath Analyzer and mobile appCollaboration will evaluate the impact of the OMED solution on the digestive health and quality of life of participants in a w
Zyme Communications
Biodesix logo
Healthcare and Life Science 22 Oct 2025

Biodesix announces expanded Bio-Rad Laboratories partnership agreement to develop Droplet Digital™ PCR High Complexity Assays

Biodesix will perform the clinical validation of ddPLEX ESR1 Mutation Detection Assay for advanced breast cancer testing

Zyme Communications
ProImmune’s new headquarters at Oasis Park, Oxford
Healthcare and Life Science 22 Oct 2025

ProImmune expands into new 18,000 sq ft global headquarters enabling major expansion in immunology and life science innovation

Move follows ProImmune’s recent acquisition of Oasis Park a 70,000 sq ft Business and Light Industrial Park in Oxford, UKIncreased operational capacity enables accelerated development of ProImmune’s REVEAL® Immunogenicity System and Ankyron® target
Zyme Communications
Bio-Rad logo
Healthcare and Life Science 21 Oct 2025

Bio-Rad’s iQ-Check Enterobacteriaceae Kit validated for detection of Enterobacteriaceae in infant formula and cereals

Certified by MicroVal for Detection of Enterobacteriaceae Including Salmonella, Cronobacter, and E.coli as Indicator of Process Effectiveness to Eliminate Contaminants in Infant Formula and Related Ingredients.

Zyme Communications
Enamine
Healthcare and Life Science 21 Oct 2025

Enamine contributes to the discovery of promising broad-spectrum coronavirus antiviral

Open-science research initiative, COVID Moonshot and the AI-driven Structure-enabled Antiviral Platform (ASAP) consortium, delivered a promising pre-clinical candidate2,000 new compounds generated for the programme are now available from Enamine’s catalogue
Zyme Communications
https://mosaic-tx.com/
Healthcare and Life Science, Science and Engineering 20 Oct 2025

Mosaic Therapeutics appoints Thomas Fuchs as CEO

Former CEO of Cimeio Therapeutics, and Global Haematology Franchise Head at Roche-Genentech, brings extensive track record of strategic and operational leadershipAppointment strengthens executive leadership team and supports transition into clinical development
Zyme Communications
giles AI
Healthcare and Life Science 20 Oct 2025

giles introduces AI agent to accelerate healthcare and life science research

AI tool connects researchers to verified medical and life sciences global databases, enabling accurate extraction and summarisation of academic papers, journals, and articlesgiles will be showcased at ISPOR Europe 2025, Glasgow, 9-12th November, booth 314
Zyme Communications
Prof. Kevin Chalut, CSO and Co-Founder, and Dr. Léa Wenger, CEO and Co-Founder, Cyclana Bio	The Cyclana Bio team
Healthcare and Life Science 20 Oct 2025

Cyclana Bio raises £5M to advance drug discovery for Endometriosis

Co-led by NfX and Eka VC, investors include Cocoa VC, Wilbe, and Angel investorsInvestment will support development of whole tissue-based platform for identification of druggable targets and scaling of observational clinical trial

Cambridge, UK,

Zyme Communications
https://www.sptlabtech.com/
Healthcare and Life Science, Science and Engineering 14 Oct 2025

SPT Labtech and 10x Genomics partner to automate single cell workflows

Automated workflows will be highlighted at ASHG 2025 with customer-generated dataPartnership to enable automated workflows for 10x Genomics’ Chromium Single Cell Platform on SPT Labtech’s firefly liquid handling platform

Melbourn, UK, and Pleasa

Zyme Communications
CN BIO logo
Healthcare and Life Science 14 Oct 2025

CN Bio launches all-in-one Organ-on-a-chip system, PhysioMimix® Core

Combines single-organ, multi-organ, and higher-throughput configurations within one scalable platformFully compatible with existing PhysioMimix accessories, validated protocols, consumables, and organ model kits for seamless workflow integration 

Zyme Communications
Dr. Werner Lanthaler, CEO, FairJourney Biologics Image credit: WLan Holding
Healthcare and Life Science 08 Oct 2025

FairJourney Biologics appoints Dr. Werner Lanthaler as Chief Executive Officer

Dr.
Zyme Communications
Morten Frost, CCO, SPT Labtech	Nina Green, Vice President and General Manager of the Clinical Diagnostic Division, Agilent
Healthcare and Life Science 08 Oct 2025

SPT Labtech and Agilent introduce automated target enrichment protocols for genomic workflows

Optimized, automated protocols on SPT Labtech’s firefly®+ using Agilent’s SureSelect Max DNA Library Prep KitSupports high-throughput sequencing in clinical research, oncology, and precision medicineProtocols to be showcased at ASHG, 14th –
Zyme Communications
London Bio Innovation week Dec 2025
Healthcare and Life Science 01 Oct 2025

Five leading life science organisations collaborate on inaugural London Bio-Innovation Week

ELRIG, Life Science Integrates, Life Science Nation, One Nucleus and SLAS will provide delegates with the opportunity for cross-event partnering during London B
Zyme Communications
Bio-Rad and Gencurix
Healthcare and Life Science 01 Oct 2025

Bio-Rad extends partnership with Gencurix through strategic agreement for Droplet Digital™ PCR IVD Oncology Kits in Europe

Extended Partnership Agreement Will Expand Availability Across Europe of Gencurix’ In Vitro Diagnostic (IVD) Assays Using Droplet Digital™ PCR (ddPCR™) for Clinical Testing of Critical Oncology Biomarkers

Zyme Communications
Dr Robert Neely CSO and Co-Founder,  Tagomics
Healthcare and Life Science 30 Sep 2025

Tagomics publishes a new approach to genome-wide epigenomic profiling

Study published in ‘Cell Reports Methods’ demonstrates the strength of Tagomics’ platform for epigenomic biomarker discovery and applications in liquid biopsyActivace platform enables targeted, genome-wide profiling of unmethylated DNA regions, providing a comprehensive
Zyme Communications
Miebach’s new facilities at Abingdon Science Park, Oxford	Miebach’s new facilities at Abingdon Science Park, Oxford
Healthcare and Life Science, Property and Utilities 26 Sep 2025

Miebach Consulting doubles footprint on Abingdon Science Park

Bespoke facilities within The Science Quadrant offer additional capacity as part of ongoing growth

Zyme Communications
David James, Co-Founder and Chief Scientific Officer, SynGenSys
Healthcare and Life Science 23 Sep 2025

SynGenSys introduces NK.SET synthetic promoter library to advance natural killer cell therapies

First commercially available NK (natural killer) cell-specific promoter library enables precise and controllable gene expressionPortfolio of synthetic promoters validates SynGenSys’ platform for engineering targeted, tissue-specific gene regulation control elements

Pagination

  • First page «
  • Previous page ‹
  • …
  • Page 3
  • Page 4
  • Current page 5
  • Page 6
  • Page 7
  • …
  • Next page ›
  • Last page »
Receive our newsletter

Cambridge Network Limited is a company registered in England under company No. 3400152

The Hauser Forum, 3 Charles Babbage Road, Cambridge, CB3 0GT

Email: [email protected], Tel: 01223 746801

© 2026 Cambridge Network. All Rights Reserved.

Website by KISS